WTX-124 is a fusion protein commercialized by Werewolf Therapeutics, with a leading Phase I program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of WTX-124’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for WTX-124 is expected to reach an annual total of $12 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

WTX-124 Overview

WTX-124 is under development for the treatment of solid tumors, colon carcinoma, advanced or metastatic renal cell carcinoma and advanced or metastatic cutaneous malignant melanoma. It is novel receptor agonists for cancer immunotherapy. It is developed based on PREDATOR technology. It acts by targeting IL2Rb/IL2Rg. The drug candidate is a systemically-delivered conditionally-activated Interleukin-2 (IL-2) INDUKINE molecule

Werewolf Therapeutics Overview

Werewolf Therapeutics is a biopharmaceutical company that discovers and develops treatments for cancer. The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies for refractory and immunologically unresponsive tumors. Werewolf Therapeutics utilizes its proprietary Predator protein engineering technology platform to identify, design, optimize and validate immuno-oncology, autoimmune and inflammatory disease product candidates. It’s protein engineering technology integrates protein design elements to improve activity, stability and tumor selectivity within a single molecule. Werewolf Therapeutics is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$50.1 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$50 million in FY2021, compared to a net loss of US$15 million in FY2020. The company reported revenues of US$5 million for the third quarter ended September 2022, an increase of 19.8% over the previous quarter.

For a complete picture of WTX-124’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.